Asset

FIMEPINOSTAT

Curis Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02307240phase1completed2014-11-012019-05-31Curis, Inc.Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
NCT02674750phase2completed2016-07-012019-05-28Curis, Inc.Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)